Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance

2012/08/04 by Seizaburo Kashiwagi, Sanae Yoshida, Hiroki Yamaguchi +7 · 8 citations
Medicine · #Influenza Virus Research Studies #Respiratory viral infections research #Travel-related health issues

paper · doi:10.1016/j.ijantimicag.2012.06.017

Cited by

• Life-Threatening Abnormal Behavior Incidence in 10-19 Year Old Patients Administered Neuraminidase Inhibitors. [europepmc]
• Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate. [europepmc]
• Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection. [europepmc]
• Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy. [europepmc]
• Discovery of New Ginsenol-Like Compounds with High Antiviral Activity. [europepmc]
• Antiviral Drugs in Influenza. [europepmc]
• A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review. [europepmc]
• Antiviral Drugs for Influenza and Other Respiratory Virus Infections [europepmc]